Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
10.1016/j.plaphy.2012.01.014 11 BartlingD
The primary concern with hepatic impairment is a potential change in exposure to a drug that is extensively cleared by hepatic metabolism or biliary excretion via the liver, that could impact on the pharmacodynamic action or lead to adverse effects [19]
A Randomized Trial of Induction Chemotherapy or No Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Esophageal Cancer
By Drug Type By Molecule By Distribution Channel By End User By Region
US$ 20.74
US$ 21.92
US$ 20.34
US$ 28.64
US$ 26.03
US$ 28.03
